Queensland Amyloidosis Centre

The Queensland Amyloidosis Centre is a site of world leading research to understand, prevent and ultimately cure amyloidosis

The Queensland Amyloidosis Centre is actively pursuing research to improve the diagnosis and management of patients with amyloidosis. Current research projects include:

  • A study of the epidemiology of systemic amyloidosis in Queensland. This study will provide the first information on how common amyloidosis is in Australia.
  • Fluorine-18-labelled florbetaben positron emission tomography to monitor cardiac amyloidosis. This study will see if PET scanning can be used to better monitor patients with cardiac amyloidosis.
  • Improving diagnosis of amyloidosis by immunohistochemistry. A scientist from the Pathology Queensland PAH Anatomical Pathology laboratory has traveled to the UK National Amyloidosis Centre to bring back and improve local diagnsotic immunohistochemistry techniques.
  • Sebia FLC assay for measuring serum free light chains in patients with AL amyloidosis. This study aims to see if a new way of measuring serum free light chains is better than existing tests.
  • A Phase 3 Randomized, Controlled, Open-Label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician’s Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis. This international study is testing wither a new drug called ixazomib (=MLN9708)  is better than other standard treatments for patients with AL amyloidosis whose disease has not responded or come back after initial treatment.
  • A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared with CyBorD alone in Newly Diagnosed Systemic Light-Chain (AL) Amyloidosis. This international study is testing whether a new drug called daratumumab can improve the outcome of newly diagnosed patients with AL amyloidosis when added to the standard chemotherapy regimen called CyBorD.
  • Natural history of ATTRwt. The cardiology department is leading an Australian-wide study to better understand ATTRwt (=senile cardiac amyloidosis)

Publications.